Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC Vaccine for Stage IV Melanoma
NCT00125749Phase 2Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Jul 2005
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WT1/hTERT/Survivin-loaded dendritic cell vaccine in melanoma, sponsored by Baylor Scott & White Research Institute. Primary endpoints: Safety and tolerability of the novel DC vaccination product at 3 years, Feasibility of a novel approach to DC manufacture at 3 years and 1 more. Started Jul 2005; status: completed.
02
Drugs
WT1/hTERT/Survivin-loaded dendritic cell vaccine
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00125749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125749.